These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 36097802)
1. Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor-Positive and HER-2-Negative Breast Cancer with Neoadjuvant Chemotherapy. Lee EG; Lee DE; Kim HH; Han JH; Lee S; Kang HS; Lee ES; Chae H; Sim SH; Lee KS; Kwon Y; Jung SY Cancer Res Treat; 2023 Apr; 55(2):542-550. PubMed ID: 36097802 [TBL] [Abstract][Full Text] [Related]
2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China. Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898 [TBL] [Abstract][Full Text] [Related]
3. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy. Shi Z; Liu Y; Zhang S; Cai S; Liu X; Meng J; Zhang J Discov Oncol; 2023 Apr; 14(1):49. PubMed ID: 37099044 [TBL] [Abstract][Full Text] [Related]
5. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value. Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089 [TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342 [TBL] [Abstract][Full Text] [Related]
7. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263 [TBL] [Abstract][Full Text] [Related]
8. Correlation between androgen receptor expression and pathological response rate in pre-operative HER2-positive breast cancer patients. Li N; Wu J; Qi X; Yang Q; Liu R; Yang Y; Li C; Huang M; Lin M; Wang C; Cha Z; Hou X; Luo L; Ge F; Chen W J Cancer Res Clin Oncol; 2023 Sep; 149(12):10109-10117. PubMed ID: 37264265 [TBL] [Abstract][Full Text] [Related]
9. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334 [TBL] [Abstract][Full Text] [Related]
10. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Tan QX; Qin QH; Yang WP; Mo QG; Wei CY Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769 [TBL] [Abstract][Full Text] [Related]
12. Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. Choi HJ; Lee JH; Jung CS; Lee JE; Jung YJ; Lee S; Kang SK; Kim HY Oncology; 2022; 100(10):529-535. PubMed ID: 35882211 [TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients. Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527 [TBL] [Abstract][Full Text] [Related]
14. Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer. Shi Y; Lu H; Zhang Y Breast Cancer Res Treat; 2024 Jul; 206(2):387-395. PubMed ID: 38658447 [TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Houssami N; Macaskill P; von Minckwitz G; Marinovich ML; Mamounas E Eur J Cancer; 2012 Dec; 48(18):3342-54. PubMed ID: 22766518 [TBL] [Abstract][Full Text] [Related]
16. Relationship Between Breast and Axillary Pathologic Complete Response in Women Receiving Neoadjuvant Chemotherapy for Breast Cancer. Lim DW; Greene BD; Look Hong NJ Ann Surg Oncol; 2021 Oct; 28(10):5495-5506. PubMed ID: 34374914 [TBL] [Abstract][Full Text] [Related]
17. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis. Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250 [TBL] [Abstract][Full Text] [Related]
18. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer. Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288 [TBL] [Abstract][Full Text] [Related]
19. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab. Ohzawa H; Sakatani T; Niki T; Yasuda Y; Hozumi Y Breast Cancer; 2014 Sep; 21(5):563-70. PubMed ID: 23108629 [TBL] [Abstract][Full Text] [Related]
20. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer. Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]